Shamburg News · 8-K filed Oct 23, 2026, 8:38 AM EDT
Aardvark Therapeutics Reports Exploratory Data From Terminated HERO and Open-Label Extension Trials
AARD · Aardvark Therapeutics, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On October 23, 2026, Aardvark Therapeutics, Inc. reported exploratory efficacy data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101 in Prader-Willi syndrome. The HERO trial randomized 67 of 90 planned participants before early termination, and the company states all efficacy data are exploratory. The company also said it plans to request an FDA meeting on a new Phase 3 design and hosted an investor webinar the same day.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-429509.
Written from the filing by Shamburg Markets. Figures are as reported by the company.